Consortium of Multiple Sclerosis Centers (CMSC) and Atara Biotherapeutics on Thursday – June 10, 2021 at 7:00 PM – 8:00 PM ET on an informational webinar. Dr. Scott Newsome, President of the CMSC and Dr. Mark Freedman, internationally noted MS clinician and researcher, will be joined by Dr. Jonathan Willmer, Vice President, Clinical Sciences of Atara Bio and Dr. AJ Joshi, Chief Medical Officer of Atara Bio to discuss current research activities in MS.
Click here to watch the webinar.
EBV and MS
Epstein-Barr Virus (EBV) is associated with a wide range of hematologic malignancies and solid tumors, as well as certain autoimmune conditions such as multiple sclerosis (MS). T‑Cells are a critical component of the body’s immune system and can selectively target EBV believed to be important in the pathogenesis of MS.
About Multiple Sclerosis (MS)
MS is a chronic neurological autoimmune disease that affects an estimated 2.3 million people around the world. Relapsing-remitting MS (RRMS) is the most common form of MS and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. Despite available disease-modifying treatments, most individuals with RRMS continue to experience disease activity and disability progression.
Progressive MS (PMS) is a severe form of the disease with few therapeutic options. PMS comprises two conditions, both characterized by persistent progression and worsening of MS symptoms and physical disability over time. Primary Progressive MS (PPMS) occurs when continuous progressive disease is present at diagnosis and occurs in approximately 15% of newly diagnosed cases. Secondary Progressive MS (SPMS) initially begins as RRMS and develops into a progressive form. Up to 80% of people with RRMS will eventually develop SPMS. There is substantial unmet medical need for new and effective therapies for patients with PPMS and SPMS. Most treatment options that work well in reducing flares in RRMS have not been shown to be effective in slowing or reversing disability in PMS.
About Atara Biotherapeutics
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. We utilize T‑Cells from donors with healthy immune function, with the goal to specifically recognize and target cancerous or diseased cells in patients without affecting normal cells. Our investigational off-the-shelf T‑Cells are intended for rapid delivery from inventory to patients.
